Articles On Cryosite (ASX:CTE)

Title Source Codes Date
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Stockhead CTE 2 weeks ago
Biocurious: Stiff competition aside, cryopreserver Vitrafy has the ingredients for success

Vitrafy listed yesterday at a 7.6% premium after raising $35 million The company claims its freezing and thawing technique better preserves bodily tissue The company was co-founded by former Masterchef winner Brent Owens Winning MasterChe...

Stockhead CTE 3 weeks ago
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Stockhead CTE 1 month ago
S&P 500 reaches another record high

  Stocks climbed for a second consecutive session on Wednesday, with the S&P 500 and Dow Jones Industrial Average reaching record highs as technology shares surged and investors brushed aside geopolitical worries. The S&P 500 rose 0...

ShareCafe CTE 2 months ago
S&P 500 reaches another record high

Stocks climbed for a second consecutive session on Wednesday, with the S&P 500 and Dow Jones Industrial Average reaching record highs as technology shares surged and investors brushed aside geopolitical worries. The S&P 500 rose 0.7...

ShareCafe CTE 2 months ago
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Stockhead CTE 2 months ago
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Stockhead CTE 3 months ago
Hot Money Monday: Should you only go for fully franked dividend paying stocks?

Many ASX top dividend payers don’t offer fully franked dividends What’s the difference between franked and unfranked dividends? And which is better?    It’s that time of the year again when companies dole out dividends to loyal investors....

Stockhead CTE 3 months ago
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

Stockhead CTE 4 months ago
ASX July Winners: The best 50 stocks in a strong month for markets

S&P/ASX 200 had its best month of the year in July finishing up 4% to record high S&P Dow Jones Indices says large cap companies continued to lead the market in July Consumer discretionary and real estate topped July sector leaders...

Stockhead CTE 4 months ago
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

Stockhead CTE 4 months ago
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Stockhead CTE 5 months ago
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Stockhead CTE 6 months ago
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Stockhead CTE 7 months ago
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

Stockhead CTE 7 months ago
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Stockhead CTE 7 months ago
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead CTE 9 months ago
Closing Bell: Smug ASX ends Tuesday higher, but not much better

The ASX benchmark has ended Tuesday higher 8 of 11 sectors in the green Small caps led by Plenti Group (ASX:PLT), InteliCare (ASX:ICR) The local market has trimmed some of its early gains (wussed out) after jumping out of the blocks in...

Stockhead CTE 1 year ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead CTE 1 year ago
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Stockhead CTE 1 year ago
Markets remain cautious ahead of key jobs data

  Stocks settled lower on Thursday as investors remain cautious ahead of key jobs data on Friday that could determine the next move for interest rates. The Dow Jones Industrial Average closed down 10 points, or 0.03 per cent. The S&P 50...

ShareCafe CTE 1 year ago
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Stockhead CTE 1 year ago
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead CTE 1 year ago
Major US indexes fall as Fed rate hike fears return

  Stocks sold off Wednesday, continuing the sluggish start to September, as concerns mounted that the Federal Reserve may not be done hiking interest rates. The Dow Jones Industrial Average sank 198.78 points, or 0.57 per cent, to end at 34...

ShareCafe CTE 1 year ago
Check Up: Australian biotech sector continues to be a magnet for US investors

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead CTE 1 year ago
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Stockhead CTE 1 year ago
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Stockhead CTE 1 year ago
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Stockhead CTE 1 year ago
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Stockhead CTE 1 year ago
CLOSING BELL: A massive win for Zelira’s new pain drug has polished an absolute turd of a day

The ASX 200 fell 1.37%, and the bad news kept piling up all day Inflation data knee-capped the market mid-morning, because rate hikes are on the way Two Small Caps hit triple-figure home runs today, which is kinda amazing   Welp… that was...

Stockhead CTE 1 year ago
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead CTE 1 year ago
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Stockhead CTE 1 year ago
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Stockhead CTE 1 year ago
How out of favour Biotech has a PR problem and could learn from Dr Karl

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Stockhead CTE 2 years ago
BRIEF-Cryosite Ltd Says Unaudited Trading For First Four Months Of Year Show Stable Revenues

Nov 17 (Reuters) - Cryosite Ltd: * UNAUDITED TRADING FOR FIRST FOUR MONTHS OF YEAR SHOW STABLE REVENUES BUT LOWER PROFITABILITY * FOR FIRST 4 MONTHS OF FY23, TOTAL REVENUE FLAT ON PCP AT A$3,791 MILLION Source text for Eikon: Further compan...

Kalkine Media CTE 2 years ago
Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Stockhead CTE 2 years ago
US equity markets surge off lows despite higher than expected inflation data

ShareCafeUS equity markets surge off lows despite higher than expected inflation data                    US equities finished higher in Thursday trading, near best levels after reversing a big decline from right after the open – this...

ShareCafe CTE 2 years ago
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Stockhead CTE 2 years ago
US markets rise as EV battery integration grows rapidly under Biden Administration

ShareCafeUS markets rise as EV battery integration grows rapidly under Biden Administration                    US equities were mostly higher in fairly choppy Wednesday trading. The Nasdaq Composite ground higher in choppy trading on...

ShareCafe CTE 2 years ago
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Stockhead CTE 2 years ago
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Stockhead CTE 2 years ago
Closing Bell: A lithium leak is draining the small cap battery boom

Emerging markets index closes 2.3% lower ASX200 pretty flat, maybe ahead by 0.1% March Qtr GDP rises 0.8%   The Emerging Companies Index has got a lithium leak. We don’t where, we don’t know why. It was down more than 2.7% and has kinda...

Stockhead CTE 2 years ago
Closing Bell: Markets go easy peasy lemon squeezy on Anthony Norman Albanese

Aussie markets opened slightly ahead this morning after man of the moment Anthony Norman Albanese was sworn in as the 31st prime minister and posed for a happy ALP family pic, thus ended 10 years of conservative government. Throughout the d...

Stockhead CTE 2 years ago
Check Up: Money managers are still bullish on Healthcare; here’s what they said

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Stockhead CTE 2 years ago
Top 10 at 10: These ASX stocks are unstoppable in early trade

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead CTE 2 years ago
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Stockhead CTE 2 years ago
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Stockhead CTE 2 years ago
Closing Bell: ASX flat, but volatile

ASX Emerging Companies (XEC) index has closed o.2% higher Monday Monday winners: Terramin Australia (ASX:TZN), Frontier Resources (ASX:FNT), Ardea Resources (ASX:ARL) Monday losers: Melbana Energy (ASX:MAY)   The ASX Emerging Companies...

Stockhead CTE 2 years ago
Closing Bell: Small caps rise, unemployment falls, more people accept life’s full of ups and downs

The Emerging Companies Index (XEC) climbed more than 2% higher on Thursday, before closing at 1.9%, while its benchmark colleague – the upmarket ASX 200 followed Wall Street’s ascendence, trading up a shade over 1% after the Fed lifted inte...

Stockhead CTE 2 years ago
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Stockhead CTE 2 years ago